133 related articles for article (PubMed ID: 35946566)
21. Pharmacogenetics in American Indian populations: analysis of CYP2D6, CYP3A4, CYP3A5, and CYP2C9 in the Confederated Salish and Kootenai Tribes.
Fohner A; Muzquiz LI; Austin MA; Gaedigk A; Gordon A; Thornton T; Rieder MJ; Pershouse MA; Putnam EA; Howlett K; Beatty P; Thummel KE; Woodahl EL
Pharmacogenet Genomics; 2013 Aug; 23(8):403-14. PubMed ID: 23778323
[TBL] [Abstract][Full Text] [Related]
22. Potential influence of being overweight on the development of hepatic dysfunction in Japanese patients with EGFR-mutated non-small cell lung cancer undergoing gefitinib monotherapy: the Okayama Lung Cancer Study Group experience.
Oda N; Hotta K; Yoshioka H; Kudo K; Ichihara E; Kato Y; Ninomiya K; Minami D; Ninomiya T; Kubo T; Ohashi K; Sato A; Takigawa N; Tabata M; Tanimoto M; Kiura K
Cancer Chemother Pharmacol; 2016 Nov; 78(5):941-947. PubMed ID: 27590708
[TBL] [Abstract][Full Text] [Related]
23. Bioactivation of the epidermal growth factor receptor inhibitor gefitinib: implications for pulmonary and hepatic toxicities.
Li X; Kamenecka TM; Cameron MD
Chem Res Toxicol; 2009 Oct; 22(10):1736-42. PubMed ID: 19803472
[TBL] [Abstract][Full Text] [Related]
24. Comparison of adverse events of erlotinib with those of gefitinib in patients with non-small cell lung cancer: a case-control study in a Japanese population.
Suzumura T; Kimura T; Kudoh S; Umekawa K; Nagata M; Tanaka H; Mitsuoka S; Yoshimura N; Kira Y; Hirata K
Osaka City Med J; 2012 Jun; 58(1):25-34. PubMed ID: 23094511
[TBL] [Abstract][Full Text] [Related]
25. First-line gefitinib treatment in elderly patients (aged ≥75 years) with non-small cell lung cancer harboring EGFR mutations.
Kuwako T; Imai H; Masuda T; Miura Y; Seki K; Yoshino R; Kaira K; Utsugi M; Shimizu K; Sunaga N; Tomizawa Y; Ishihara S; Ishizuka T; Mogi A; Hisada T; Minato K; Takise A; Saito R; Yamada M
Cancer Chemother Pharmacol; 2015 Oct; 76(4):761-9. PubMed ID: 26254024
[TBL] [Abstract][Full Text] [Related]
26. [Effect of rs2293347 Polymorphism in EGFR on the Clinical Efficacy of Gefitinib
in Patients with Non-small Cell Lung Cancer].
Ma F; Xu B; Lin D; Sun T; Shi Y
Zhongguo Fei Ai Za Zhi; 2011 Aug; 14(8):642-5. PubMed ID: 21859544
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study.
Nio Y; Ishida H; Matsumoto N; Kusumoto S; Kubota Y; Tsunoda T; Sasaki Y; Fujita KI
BMC Pulm Med; 2022 Nov; 22(1):454. PubMed ID: 36451169
[TBL] [Abstract][Full Text] [Related]
28. The gefitinib dose reduction on survival outcomes in epidermal growth factor receptor mutant non-small cell lung cancer.
Sim SH; Keam B; Kim DW; Kim TM; Lee SH; Chung DH; Heo DS
J Cancer Res Clin Oncol; 2014 Dec; 140(12):2135-42. PubMed ID: 25005787
[TBL] [Abstract][Full Text] [Related]
29. Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers.
Belmonte C; Ochoa D; Román M; Saiz-Rodríguez M; Wojnicz A; Gómez-Sánchez CI; Martín-Vílchez S; Abad-Santos F
Basic Clin Pharmacol Toxicol; 2018 Jun; 122(6):596-605. PubMed ID: 29325225
[TBL] [Abstract][Full Text] [Related]
30. Polymorphisms of NF-κB pathway genes influence adverse drug reactions of gefitinib in NSCLC patients.
Xin S; Zhao Y; Wang C; Huang Y; Zhuang W; Ma Y; Huang M; Xu X; Wang X; Zhang L
Pharmacogenomics J; 2020 Apr; 20(2):285-293. PubMed ID: 31664190
[TBL] [Abstract][Full Text] [Related]
31. Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized trial.
Zhou Q; Cheng Y; Yang JJ; Zhao MF; Zhang L; Zhang XC; Chen ZH; Yan HH; Song Y; Chen JH; Feng WN; Xu CR; Wang Z; Chen HJ; Zhong WZ; Liu YP; Wu YL
Ann Oncol; 2014 Dec; 25(12):2385-2391. PubMed ID: 25281710
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness of Tyrosine Kinase Inhibitors in Japanese Patients with Non-small Cell Lung Cancer Harboring Minor Epidermal Growth Factor Receptor Mutations: Results from a Multicenter Retrospective Study (HANSHIN Oncology Group 0212).
Otsuka T; Mori M; Yano Y; Uchida J; Nishino K; Kaji R; Hata A; Hattori Y; Urata Y; Kaneda T; Tachihara M; Imamura F; Katakami N; Negoro S; Morita S; Yokota S
Anticancer Res; 2015 Jul; 35(7):3885-91. PubMed ID: 26124334
[TBL] [Abstract][Full Text] [Related]
33. Functional characterization of wild-type and 24 CYP2D6 allelic variants on gefitinib metabolism in vitro.
Fang P; Zheng X; He J; Ge H; Tang P; Cai J; Hu G
Drug Des Devel Ther; 2017; 11():1283-1290. PubMed ID: 28461741
[TBL] [Abstract][Full Text] [Related]
34. Gefitinib for advanced non-small cell lung cancer.
Sim EH; Yang IA; Wood-Baker R; Bowman RV; Fong KM
Cochrane Database Syst Rev; 2018 Jan; 1(1):CD006847. PubMed ID: 29336009
[TBL] [Abstract][Full Text] [Related]
35. A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations.
Asahina H; Yamazaki K; Kinoshita I; Sukoh N; Harada M; Yokouchi H; Ishida T; Ogura S; Kojima T; Okamoto Y; Fujita Y; Dosaka-Akita H; Isobe H; Nishimura M
Br J Cancer; 2006 Oct; 95(8):998-1004. PubMed ID: 17047648
[TBL] [Abstract][Full Text] [Related]
36. Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations.
Cheng Y; Murakami H; Yang PC; He J; Nakagawa K; Kang JH; Kim JH; Wang X; Enatsu S; Puri T; Orlando M; Yang JC
J Clin Oncol; 2016 Sep; 34(27):3258-66. PubMed ID: 27507876
[TBL] [Abstract][Full Text] [Related]
37. Polymorphisms of EGFR predict clinical outcome in advanced non-small-cell lung cancer patients treated with Gefitinib.
Ma F; Sun T; Shi Y; Yu D; Tan W; Yang M; Wu C; Chu D; Sun Y; Xu B; Lin D
Lung Cancer; 2009 Oct; 66(1):114-9. PubMed ID: 19201048
[TBL] [Abstract][Full Text] [Related]
38. The effect of gefitinib in patients with postoperative recurrent non-small cell lung cancer harboring mutations of the epidermal growth factor receptor.
Ko R; Kenmotsu H; Hisamatsu Y; Akamatsu H; Omori S; Nakashima K; Oyakawa T; Wakuda K; Shukuya T; Ono A; Imai H; Taira T; Naito T; Murakami H; Mori K; Endo M; Ohde Y; Takahashi K; Takahashi T
Int J Clin Oncol; 2015 Aug; 20(4):668-73. PubMed ID: 25343946
[TBL] [Abstract][Full Text] [Related]
39. Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring EGFR mutations.
Ichihara E; Hotta K; Takigawa N; Kudo K; Kato Y; Honda Y; Hayakawa H; Minami D; Sato A; Tabata M; Tanimoto M; Kiura K
Lung Cancer; 2013 Sep; 81(3):435-439. PubMed ID: 23809059
[TBL] [Abstract][Full Text] [Related]
40. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.
de Leon J; Susce MT; Murray-Carmichael E
Mol Diagn Ther; 2006; 10(3):135-51. PubMed ID: 16771600
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
